Jeremiah Chin, BioPharma Account Manager and Strategic Healthcare Consultant, shared a post on LinkedIn:
“ESMO Asia 2025
Another giant.
Prof Ravindran Kanesvaran is more than an oncologist he is a catalyst for change in how the world understands and treats cancer in the ageing population. As Chairman and Senior Consultant at the National Cancer Centre Singapore, Professor at Duke-NUS, distinguished global leader in geriatric oncology, and Co-Director of the Singapore Translational Cancer Consortium, he has helped shape cancer care locally and internationally.
From pioneering Southeast Asia’s first geriatric oncology service to leading global phase-III trials and influencing ESMO, SIOG and international cancer policy, Prof Kanesvaran exemplifies what it means to drive your destiny. His journey reminds us that purpose is not found in titles it is found in the impact we leave on lives, communities, and the future of medicine.
As ESMO Asia 2025 looks beyond innovation into humanity, Prof Kanesvaran stands as a voice of clarity: the future of cancer care belongs not just to technology, but to empathy, ageing with dignity, and the courage to lead where no one has led before.”
More posts about ESMO Asia 2025 on OncoDaily.
